Barely Significant
← all excerpts

Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial.

Nat Med · 2025 · PMC12705426 · PMID 41053449

Europe PMCDOI
1
hedged sentence
0.0860
closest p · 1.7× alpha
0.0860
boldest claim

The sentences

did not reach statistical significanceP = 0.086so close (0.05 < p ≤ 0.1)
A numerically higher proportion of patients treated with SLK 60-mg NI versus PBO achieved ACR50, but this difference did not reach statistical significance (36.6% versus 20.0%; P = 0.086; Fig. 2a and Extended Data Table 1 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.